Home
NewsNewsLG Chem’s App for Infertility and Pregnancy Preparation, Bloom, brings together fertility education, treatment explanations, emotional support, and preparation tools in one digital platform. Designed as a companion rather than a clinical service, the app addresses growing information gaps faced by individuals and couples navigating infertility and pregnancy preparation.
Infertility has become a significant concern in modern society, with delayed marriages, environmental factors, and lifestyle changes contributing to increased fertility challenges. As more individuals and couples seek support during pregnancy preparation, digital healthcare tools are emerging to bridge the information gap. One such platform is the Bloom app for infertility and pregnancy preparation, developed by LG Chem in collaboration with leading reproductive medicine organizations in Korea.
Unveiled in September 2025, Bloom isn’t just another health app. It is a digital healthcare platform designed to give people scientifically grounded guidance on fertility, infertility, and preparing the body and mind for pregnancy. LG Chem positioned Bloom as a companion for women aiming to conceive, couples facing difficulties conceiving, and individuals looking toward future fertility preservation. The app’s name carries metaphorical weight: a blend of new life, hope, and the full bloom of possibility.
Infertility is no longer a fringe issue. Demographic shifts, like later marriages and changing lifestyles, mean that increasing numbers of couples confront conception challenges. But beyond statistics, the emotional landscape can be heavy: confusion, countless online searches, and uncertainty about what steps to take next. LG Chem’s internal research suggested that while information exists, it’s scattered, technical, and often hard for laypeople to parse. Bloom aims to centralize that information and make it usable.
The Bloom app for infertility and pregnancy preparation includes several informational and support components:
A few months after its release, Bloom gained industry validation. In December 2025, the app won the grand prize in the medical service category at the Smart App Awards, one of Korea’s respected tech recognitions, judged by a 4,000-member panel assessing design, user interface, content quality, and technological innovation.
The award citation emphasized Bloom’s scientific approach to supporting both infertility and pregnancy preparation, acknowledging that these are not purely personal concerns but broader public health issues. Such recognition suggests that the app’s design aligns with real-world needs, not just corporate ambition.
While the Bloom app for infertility and pregnancy preparation serves as a comprehensive information resource, it functions as a supplementary tool to professional medical consultation. The app provides educational content and practical guidance but does not replace individualized medical advice from fertility specialists or reproductive endocrinologists.
The Bloom app for infertility and pregnancy preparation represents an effort to consolidate infertility-related information, emotional support resources, and practical preparation materials into a single digital platform. By providing expert-verified content and community features, the Bloom app for infertility and pregnancy preparation addresses some of the informational and emotional needs individuals and couples face during pregnancy preparation and infertility treatment journeys.
A groundbreaking Nature Medicine study compares AI deep learning against expert embryologists in selecting embryos. While pregnancy rates remain comparable, the study uncovers a massive advantage in efficiency that could revolutionize IVF labs worldwide. Discover how AI-driven embryo selection accuracy is reshaping the future of fertility treatment.
FertilAI has received EU MDR clearance for tools advancing Predictive AI in Fertility through its Fertilane platform. StimAI and OvuPredict help clinicians optimise IVF timing, predict ovulation and improve scheduling efficiency. The technology supports scalable fertility care, reduced monitoring needs and better patient treatment experiences globally.
The Ferring Global Fertility Monitor has been launched by Ferring Pharmaceuticals and Gallup to examine fertility trends in 70 countries. Through large-scale surveys, the project will explore economic, social, and cultural influences on parenthood decisions. Insights are expected to guide policy, healthcare planning, and future demographic strategies.
Maven Clinic has expanded its Fertility and Family Building program with earlier diagnostics, wearable integration, and AI-powered personalised care. The enhanced platform supports faster diagnosis, improved treatment decisions, and condition-specific pathways for PCOS, endometriosis, and oncofertility. The rollout continues through 2026 with added innovations and partnerships.
Germany is debating the legalization of egg donation in Germany, challenging decades-old restrictions under the Embryo Protection Act. Experts argue reform is overdue to align with modern reproductive science, reduce fertility tourism, and improve patient care, while policymakers work to balance ethical concerns with growing demand for advanced fertility treatments.
A new review highlights the link from Forever Chemicals to reduced ART outcomes, showing how PFAS exposure impacts fertility, pregnancy, and reproductive health. The findings raise urgent concerns for IVF patients and call for stronger regulation, deeper research, and systemic action to address environmental risks in reproductive medicine.
The 2027 Title X NOFO introduces a major policy shift toward addressing infertility crisis in the U.S. It mandates basic infertility services, expands male reproductive health focus, and promotes education on body literacy and lifestyle factors, aiming to support family formation alongside traditional contraceptive services.
